Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) EBITDA
Bio-Techne Corp's EBITDA for fiscal 2026 was $349.2M, up 64.6% from $212.2M in fiscal 2025. Over the past ten years it has ranged from $180.6M (fiscal 2017) to $406.2M (fiscal 2023); the current reading is higher than 83% of that period. Bio-Techne Corp ranks 12th of 600 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $349.2M | 64.62% |
| FY2025 | $212.2M | (33.37%) |
| FY2024 | $318.4M | (21.61%) |
| FY2023 | $406.2M | 2.14% |
| FY2022 | $397.7M | 22.34% |
| FY2021 | $325.0M | 35.35% |
| FY2020 | $240.2M | 6.79% |
| FY2019 | $224.9M | 12.09% |
| FY2018 | $200.6M | 11.08% |
| FY2017 | $180.6M | (6.59%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $98.4M | (1.25%) |
| Mar 2026 | $99.7M | 25.89% |
| Dec 2025 | $79.2M | 9.96% |
| Sep 2025 | $72.0M | 2,113.96% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TECH Bio-Techne Corp | $349.2M |
| BMRN BioMarin Pharmaceutical Inc. compare | $297.4M |
| KRYS Krystal Biotech, Inc. compare | $204.4M |
| CORT Corcept Therapeutics Incorporated compare | $3.7M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$315.2M |
| BBIO BridgeBio Pharma, Inc. compare | −$486.1M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TECH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement